News
Purespring Therapeutics to Present at Piper Sandler’s 37th Annual Healthcare Conference
November 25, 2025

Purespring Therapeutics to Present at Piper Sandler’s 37th Annual Healthcare Conference

London – 25 November 2025 Purespring Therapeutics, a precision nephrology company leading the development of targeted, first-in-class genetic therapies to preserve kidney function, today announced…
Read More
Purespring to present three posters at the American Society of Nephrology Kidney Week 2025
November 4, 2025

Purespring to present three posters at the American Society of Nephrology Kidney Week 2025

New information to be presented on the study design and methodology of Purespring’s Phase I/II trial of PS-002, an AAV-based therapy delivering the complement factor…
Read More
Purespring Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
October 14, 2025

Purespring Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference

Members of the Purespring management team will present at Chardan’s 9th Annual Genetic Medicines Conference. London – 14 October 2025 Purespring Therapeutics, a precision nephrology…
Read More
Purespring Therapeutics to Participate in the 2025 BofA Healthcare Trailblazers Private Company Conference
September 10, 2025

Purespring Therapeutics to Participate in the 2025 BofA Healthcare Trailblazers Private Company Conference

Members of the Purespring management team will participate in the 2025 Bank of America Healthcare Trailblazers Private Company Conference. London – 10 September 2025 Purespring…
Read More
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
August 15, 2025

Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance…
Read More
Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)
July 9, 2025

Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)

PS-002, Purespring’s lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathy IND clearance follows the granting of European…
Read More
Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)
April 28, 2025

Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)

EMA designation provides orphan status to medicines being developed for rare conditions that are intended for the diagnosis, prevention or treatment of diseases affecting fewer…
Read More
Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer
March 12, 2025

Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer

Haseeb Ahmad brings over 25 years of leadership experience in life sciences, most recently serving as President of Novartis Europe and will lead the Company…
Read More
Purespring Therapeutics presents new preclinical data on novel gene therapy for IgA Nephropathy at ASN Kidney Week 2024
October 28, 2024

Purespring Therapeutics presents new preclinical data on novel gene therapy for IgA Nephropathy at ASN Kidney Week 2024

Results from the study underpin the potential of Purespring’s lead AAV gene therapy programme, PS-002, as an important novel modality to treat IgAN Data support…
Read More
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
October 9, 2024

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases

Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde Healthcare, Forbion, British Patient Capital and founding investor Syncona Funds raised will support Purespring in…
Read More
Q&A with Alice Brown
July 24, 2024

Q&A with Alice Brown

Can you tell us a bit about yourself and your background and what initially brought you to Purespring? My background is in biochemistry and immunology,…
Read More
Purespring Therapeutics presents preclinical data at the 61st ERA Congress
May 24, 2024

Purespring Therapeutics presents preclinical data at the 61st ERA Congress

Data establishes the potential of AAV gene therapy to deliver transgenes to the podocyte to replace defective genes or to modulate protein production Data underpin…
Read More
Q&A with Fredrik Erlandsson
March 6, 2024

Q&A with Fredrik Erlandsson

When and how did you first get involved with Purespring? Purespring caught my attention when I was looking for exciting new developments in nephrology.  At…
Read More
Purespring appoints Fredrik Erlandsson as Chief Medical Officer and Peter Mulcahy as Chief People Officer
September 6, 2023

Purespring appoints Fredrik Erlandsson as Chief Medical Officer and Peter Mulcahy as Chief People Officer

Appointments of Fredrik and Peter complete build-out of senior team. London— 6 September 2023 Purespring Therapeutics, a pioneering gene therapy company focused on transforming the…
Read More
Purespring strengthens senior leadership with appointment of Chief Medical Officer and Chief Development Officer
September 1, 2023

Purespring strengthens senior leadership with appointment of Chief Medical Officer and Chief Development Officer

Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, announces the appointments of Dr Ronny Renfurm as Chief Medical…
Read More
Purespring Therapeutics and SwanBio Therapeutics announce licensing agreement for use of FunSel screening platform
July 18, 2022

Purespring Therapeutics and SwanBio Therapeutics announce licensing agreement for use of FunSel screening platform

FunSel is Purespring’s proprietary in-vivo ‘gene search engine’, which allows functional selection of therapeutic factors unconstrained by previous drug discovery bias SwanBio will use FunSel…
Read More
Syncona founds Purespring with a £45m Series A Financing
July 30, 2021

Syncona founds Purespring with a £45m Series A Financing

Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, announces the foundation of a…
Read More
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
August 15, 2025

Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance…
Read More
Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)
July 9, 2025

Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)

PS-002, Purespring’s lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathy IND clearance follows the granting of European…
Read More
Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer
March 12, 2025

Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer

Haseeb Ahmad brings over 25 years of leadership experience in life sciences, most recently serving as President of Novartis Europe and will lead the Company…
Read More
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
October 9, 2024

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases

Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde Healthcare, Forbion, British Patient Capital and founding investor Syncona Funds raised will support Purespring in…
Read More
Purespring appoints Fredrik Erlandsson as Chief Medical Officer and Peter Mulcahy as Chief People Officer
September 6, 2023

Purespring appoints Fredrik Erlandsson as Chief Medical Officer and Peter Mulcahy as Chief People Officer

Appointments of Fredrik and Peter complete build-out of senior team. London— 6 September 2023 Purespring Therapeutics, a pioneering gene therapy company focused on transforming the…
Read More
Purespring strengthens senior leadership with appointment of Chief Medical Officer and Chief Development Officer
September 1, 2023

Purespring strengthens senior leadership with appointment of Chief Medical Officer and Chief Development Officer

Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, announces the appointments of Dr Ronny Renfurm as Chief Medical…
Read More
Purespring Therapeutics and SwanBio Therapeutics announce licensing agreement for use of FunSel screening platform
July 18, 2022

Purespring Therapeutics and SwanBio Therapeutics announce licensing agreement for use of FunSel screening platform

FunSel is Purespring’s proprietary in-vivo ‘gene search engine’, which allows functional selection of therapeutic factors unconstrained by previous drug discovery bias SwanBio will use FunSel…
Read More
Syncona founds Purespring with a £45m Series A Financing
July 30, 2021

Syncona founds Purespring with a £45m Series A Financing

Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, announces the foundation of a…
Read More
Q&A with Alice Brown
July 24, 2024

Q&A with Alice Brown

Can you tell us a bit about yourself and your background and what initially brought you to Purespring? My background is in biochemistry and immunology,…
Read More
Q&A with Fredrik Erlandsson
March 6, 2024

Q&A with Fredrik Erlandsson

When and how did you first get involved with Purespring? Purespring caught my attention when I was looking for exciting new developments in nephrology.  At…
Read More